Literature DB >> 34097471

The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.

Souwelimatou Amadou Amani1, Gillian A Lang1, Jimmy D Ballard1, Mark L Lang1.   

Abstract

The pathology associated with Clostridioides difficile disease is caused in large part by TcdB, an intracellular bacterial toxin that inactivates small GTPases. Despite C. difficile causing enteric disease, antitoxin IgG is a clear correlate of protection against infection-associated pathology. Immunization with TcdB-based immunogens or passive transfer of monoclonal antibodies specific for the TcdB carboxy-terminal domain (CTD) confers protection following C. difficile infection. Whether the mechanism by which circulating IgG is delivered to the gut depends on specific receptor-mediated transport or is solely reflective of infection-induced damage to the gut remains unclear. Here, we tested the hypothesis that neonatal Fc receptor (FcRn) is required for the delivery of systemic TcdB-specific IgG to the gut and protection against C. difficile-associated pathology. FcRn-expressing mice and FcRn-deficient littermates were immunized subcutaneously with Alhydrogel adjuvant-adsorbed CTD before challenge with live C. difficile spores. FcRn was required for the delivery of systemic TcdB-specific IgG to the gut and for vaccine-induced protection against C. difficile-associated disease. The lack of FcRn expression had minimal effects on the composition of the gut microbiome and did not affect susceptibility to C. difficile infection in nonimmunized mice. In further experiments, intraperitoneal injection of immune sera in FcRn-deficient mice led to the transport of protective IgG to the gut independently of infection, confirming a reported method of bypassing the FcRn. Our results reveal an FcRn-dependent mechanism by which systemic immunization-induced IgG protects the gut during enteric C. difficile infection. These findings may be beneficial for the targeting of C. difficile-specific IgG to the gut.

Entities:  

Keywords:  Clostridioides difficile; FcRn; adjuvant; antibodies; antibody; gut; total; toxin; toxins

Mesh:

Substances:

Year:  2021        PMID: 34097471      PMCID: PMC8445184          DOI: 10.1128/IAI.00274-21

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Deletion of a 19-Amino-Acid Region in Clostridioides difficile TcdB2 Results in Spontaneous Autoprocessing and Reduced Cell Binding and Provides a Nontoxic Immunogen for Vaccination.

Authors:  Sarah J Bland; Jason L Larabee; Tyler M Shadid; Mark L Lang; Jimmy D Ballard
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

2.  Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

Authors:  Masaru Yoshida; Kanna Kobayashi; Timothy T Kuo; Lynn Bry; Jonathan N Glickman; Steven M Claypool; Arthur Kaser; Takashi Nagaishi; Darren E Higgins; Emiko Mizoguchi; Yoshio Wakatsuki; Derry C Roopenian; Atsushi Mizoguchi; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

3.  Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion.

Authors:  Souwelimatou Amadou Amani; Tyler Shadid; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

4.  Isolation and characterization of an Fc receptor from neonatal rat small intestine.

Authors:  N E Simister; A R Rees
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

5.  Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.

Authors:  Z Zhang; X Chen; L D Hernandez; P Lipari; A Flattery; S-C Chen; S Kramer; J D Polishook; F Racine; H Cape; C P Kelly; A G Therien
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

Review 6.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Authors:  Jonathan T Sockolosky; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2015-02-19       Impact factor: 15.470

7.  Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line.

Authors:  B L Dickinson; K Badizadegan; Z Wu; J C Ahouse; X Zhu; N E Simister; R S Blumberg; W I Lencer
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

8.  Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

Authors:  Swati B Gupta; Vinay Mehta; Erik R Dubberke; Xuemei Zhao; Mary Beth Dorr; Dalya Guris; Deborah Molrine; Mark Leney; Mark Miller; Marilyne Dupin; T Christopher Mast
Journal:  Clin Infect Dis       Date:  2016-06-30       Impact factor: 9.079

Review 9.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

Review 10.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

View more
  1 in total

Review 1.  Host Immune Responses to Clostridioides difficile: Toxins and Beyond.

Authors:  Britt Nibbering; Dale N Gerding; Ed J Kuijper; Romy D Zwittink; Wiep Klaas Smits
Journal:  Front Microbiol       Date:  2021-12-21       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.